Results 91 to 100 of about 37,267 (288)

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

ESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer, Mauro Contini, Michele Emdin, Damiano Magrì, Alice Bonomi, Elisabetta Salvioni, Fabrizio Celeste, Alberico Del Torto, Claudio Passino, Christophe D.J. Capelle, Chiara Arzilli, Emiliano Fiori, Nicolò Capra, Christina Kronberger, Nikita Ermolaev, Andreas Kammerlander, Beatrice Musumeci, Giuseppe Vergaro, Vincenzo Castiglione, René Rettl, Giacomo Tini, Andrea Baggiano, Iacopo Fabiani, Susanna Sciomer, Roza Badr Eslam, Piergiuseppe Agostoni   +25 more
wiley   +1 more source

Structural relationship of κ-type light chains with AL amyloidosis: multiple deletions found in a VκIV protein [PDF]

, 1999
M A Alim, S. Yamaki, Shaikh Abu Hossain, Kazuya Takeda, Michio Kozima, Tomonori Izumi, I Takashi, T Shinoda   +7 more
openalex   +1 more source

Bilateral Chronic Subdural Nontraumatic Hematoma in a Woman Affected by AL Amyloidosis

Journal of Neurological Surgery Reports, 2015
Chronic subdural hematoma (CSDH) is a condition frequently seen in neurosurgical practice, especially among the elderly. It is often preceded by head injury, even a trivial trauma. Light chain (AL) amyloidosis is a disorder involving extracellular tissue
M. Luongo, M. Grassi, U. Godano
doaj   +1 more source

Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients [PDF]

, 1998
Raymond L. Comenzo, Evan Vosburgh, Rodney H. Falk, Vaishali Sanchorawala, Johann Reisinger, Simon W Dubrey, Laura M. Dember, John L. Berk, Görgün Akpek, Michael P. LaValley, Carl O’Hara, Charles F. Arkin, Daniel G. Wright, Martha Skinner   +13 more
openalex   +1 more source

Electron microscopic findings predict clinical outcomes in patients with non‐ischaemic cardiomyopathy

ESC Heart Failure, EarlyView.
Abstract Aims Electron microscopy reveals microstructural alterations in cardiomyocyte nuclei and myofilaments in non‐ischaemic cardiomyopathy (NICM), particularly in dilated cardiomyopathy (DCM). Nevertheless, the correlation between such observations and clinical outcomes, including prognosis and left ventricular reverse remodelling (LVRR), remains ...
Rie Higuchi, Shozo Konishi, Tomohito Ohtani, Fusako Sera, Misato Chimura, Machiko Kanzaki, Themistoklis Katsimichas, Masahiro Seo, Tetsuya Watanabe, Takahiro Okumura, Toyoaki Murohara, Hiroyuki Takahama, Atsushi Okada, Chisato Izumi, Masaru Hatano, Issei Komuro, Yoshihiko Ikeda, Yoshihiro Asano, Hatsue Ishibashi‐Ueda, Yasushi Sakata   +19 more
wiley   +1 more source

Prospects for effective treatment of AL amyloidosis? [PDF]

, 2000
Neil Iggo, Timothy J. Littlewood, Christopher G. Winearls   +2 more
openalex   +1 more source

Transthyretin amyloid cardiomyopathy in aortic stenosis patients scheduled for transcatheter aortic valve implantation

ESC Heart Failure, EarlyView.
Abbreviations: TAVI, transcatheter aortic valve implantation; ATTR‐CM, transthyretin cardiac amyloidosis. We aimed to diagnose occult ATTR‐CM in patients with severe aortic stenosis undergoing TAVI using bone scintigraphy. We verified a diagnosis of ATTR‐CM in 8 of 171 (4.7 %) consecutive aortic stenosis patients who underwent TAVI.
Margrethe Flesvig Holt, August Flø, Esra Kaya, Sophie Foss Kløve, Hege Martinsen, Kristine Amlie, Petter Storsten, Thomas Misje Mathiisen, Kristoffer Russell, Christian Hesbø Eek, Helge Skulstad, Melinda Raki, Lars Gullestad, Anders Hodt, Einar Gude, Kaspar Broch   +15 more
wiley   +1 more source

Concomitant diagnosis of primary Sjogren's syndrome and systemic AL amyloidosis [PDF]

, 2001
I. Delèvaux
openalex   +1 more source

Plasma metabolomics identifies signatures that distinguish heart failure with reduced and preserved ejection fraction

ESC Heart Failure, EarlyView.
Abstract Aims Two general phenotypes of heart failure (HF) are recognized: HF with reduced ejection fraction (HFrEF) and with preserved EF (HFpEF). To develop phenotype‐specific approaches to treatment, distinguishing biomarkers are needed. The goal of this study was to utilize quantitative metabolomics on a large, diverse population to replicate and ...
Fawaz Naeem, Teresa C. Leone, Christopher Petucci, Clarissa Shoffler, Ravindra C. Kodihalli, Tiffany Hidalgo, Cheryl Tow‐Keogh, Jessica Mancuso, Iphigenia Tzameli, Donald Bennett, John D. Groarke, Rachel J. Roth Flach, Daniel J. Rader, Daniel P. Kelly   +13 more
wiley   +1 more source

SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper

ESC Heart Failure, EarlyView.
Abstract Background Sodium glucose co‐transporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists (MRA) reduce heart failure (HF) events in patients with heart failure and mildly reduced or preserved ejection fraction (HFmr/pEF). The randomized comparison of SGLT2i/MRA combination versus SGLT2i or MRA alone requires further testing in ...
João Pedro Ferreira, Francisco Vasques‐Nóvoa, Francisca Saraiva, Ana C. Oliveira, Jorge Almeida, Ana Beatriz Batista, Arsénio Barbosa, Ana Filipa Ferreira, Cátia Costa, Diogo Santos‐Ferreira, Fernando Friões, Cândida Goncalves, João Tiago Guimarães, Marta Leite, Pedro Marques, Joana Mascarenhas, Maria Inês Matos, Catarina Pereira, Pedro Rodrigues, Abhinav Sharma, Gualter Silva, Inês Pereira‐Sousa, Carla Sousa, Faiez Zannad, Joana Pimenta, Ricardo Fontes‐Carvalho, Adelino Leite‐Moreira   +26 more
wiley   +1 more source